Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

Salman Alharbi, Maria Agustina Perusini, Sita Bhella, Mark D. Minden, Dawn Maze, Vikas Gupta, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Steven M. Chan, Aniket Bankar, Marta B. Davidson, Guillaume Richard-Carpentier, Jad Sibai, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3187–3188.

https://doi.org/10.1182/blood-2022-168662

Published: 2022

Journal Articles

Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis

Jessie J.F. Medeiros, Andy G.X. Zeng, Michelle Chan-Seng-Yue, Tristan Woo, Jessica L McLeod, Andrea Arruda, Hubert Tsui, Burhan Goraya, Jaime O. Claudio, Jenny M. Ho, James A. Kennedy, Dawn Maze, Hassan Sibai, Mark D. Minden, Jean C.Y. Wang, John E. Dick, Vikas Gupta

Blood (2022) 140 (Supplement 1): 9681–9682.

https://doi.org/10.1182/blood-2022-163722

Published: 2022

Journal Articles

Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers

Josephine Anne Lucero, Brayan Merchán, Osamah Jamal S. Jarallah, Aniket Bankar, Steven M. Chan, Marta B. Davidson, Vikas Gupta, Dawn Maze, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3166–3168.

https://doi.org/10.1182/blood-2022-168488

Published: 2022

Journal Articles

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Maria Agustina Perusini, Eshetu G. Atenafu, Aniket Bankar, Vikas Gupta, Mark D. Minden, Jad Sibai, Dawn Maze, Marta B. Davidson, Steven M. Chan, Fernando Binder, Guillaume Richard-Carpentier, Salman Alharbi, Claire Andrews, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3176–3177.

https://doi.org/10.1182/blood-2022-170121

Published: 2022

Journal Articles

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

Fatima M Khadadah, Claire Andrews, Eshetu G. Atenafu, Andre C. Schuh, Dawn Maze, Karen Yee, Osamah Jamal S. Jarallah, Mark D. Minden, Aaron D. Schimmer, Steven M. Chan, Vikas Gupta, Dennis Dong Hwan Kim, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3169–3171.

https://doi.org/10.1182/blood-2022-169342

Published: 2022

Journal Articles

The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

Blood (2022) 140 (Supplement 1): 9122–9124.

https://doi.org/10.1182/blood-2022-171107

Published: 2022

Journal Articles

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

Kenny Tang, Dawn Maze, Karen Yee, Hassan Sibai, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Andre C. Schuh, Aniket Bankar, Guillaume Richard-Carpentier, Anne Tierens, Mark D. Minden, Vikas Gupta, Jeffrey H. Lipton, Dennis Kim

Blood (2022) 140 (Supplement 1): 9608–9610.

https://doi.org/10.1182/blood-2022-166416

Published: 2022

Journal Articles

Clinical Outcomes in De Novo Versus Secondary NPM1 -Mutated AML

Elliot C. Smith, Eshetu G. Atenafu, Aniket Bankar, Steven M. Chan, Marta B. Davidson, Vikas Gupta, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dawn Maze

Blood (2022) 140 (Supplement 1): 8952–8953.

https://doi.org/10.1182/blood-2022-166939

Published: 2022

Journal Articles

Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor

James T. England, Eshetu G. Atenafu, James A. Kennedy, Burhan Goraya, Verna Cheung, Taylor Nye, Karine Gauthier, Marta B. Davidson, Aniket Bankar, Hassan Sibai, Dawn Maze, Auro Viswabandya, Vikas Gupta

Blood (2022) 140 (Supplement 1): 9724–9725.

https://doi.org/10.1182/blood-2022-165272

Published: 2022

Journal Articles

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Maria Agustina Perusini, Jad Sibai, Eshetu G. Atenafu, Aniket Bankar, Mark D. Minden, Vikas Gupta, Dawn Maze, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Guillaume Richard-Carpentier, Josephine Anne Lucero, Claire Andrews, Dennis Dong Hwan Kim, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 6039–6041.

https://doi.org/10.1182/blood-2022-169406

Published: 2022

Journal Articles

Enasidenib in Combination with Venetoclax in IDH2 -Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial

Steven M Chan, Charina Cameron, Severine Cathelin, Vikas Gupta, Dawn Maze, Mark D. Minden, Tracy Murphy, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Courtney D. DiNardo, Caroline J McNamara

Blood (2021) 138 (Supplement 1): 1263.

https://doi.org/10.1182/blood-2021-153660

Published: 2021

Journal Articles

Pregnancy Management and Outcomes in Patients with Myeloproliferative Neoplasms

Iyad Arusi, Vikas Gupta, Ann Kinga Malinowski, Nadine Shehata, Dawn Maze

Blood (2021) 138 (Supplement 1): 4615.

https://doi.org/10.1182/blood-2021-153887

Published: 2021

Journal Articles

Safety and Efficacy of JAK Inhibitor Therapy in BCR-ABL Negative MPN Patients with Underlying Portal Hypertension

Marta Davidson, Elliot Smith, Dawn Maze, Hassan Sibai, Vikas Gupta, Verna Cheung, Taylor Nye

Blood (2021) 138 (Supplement 1): 3652.

https://doi.org/10.1182/blood-2021-149696

Published: 2021

Journal Articles

Clinical Features and Long-Term Outcomes in a Molecularly-Annotated Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms

James T. England, Rouslan Kotchetkov, Hubert Tsui, Jose-Mario Capo-Chichi, Andrea Arruda, Sarah Malik, Verna Cheung, Taylor Nye, Hassan Sibai, Vikas Gupta, Dawn Maze

Blood (2021) 138 (Supplement 1): 3648.

https://doi.org/10.1182/blood-2021-148706

Published: 2021

Journal Articles

Clinical Significance of Emergent Leukocytosis in Patients with Myelofibrosis Receiving JAK Inhibitor Therapy

Radovan Vasic, MD MHS, Yuliang Shi, Andrea Arruda, MSc, Sarah Malik, Jaime Claudio, PhD, Jose-Mario Capo-Chichi, PhD, Aniket Bankar, MBBS, MD DM, Hassan Sibai, MBBS, Dawn Maze, MDFRCPC,MSc, James A. Kennedy, MDPhD, Wei Xu, PhD, Vikas Gupta, MD FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-139936

Published: 2020

Journal Articles

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Claire Andrews, Taylor Young, Eshetu G Atenafu, M.Sc., P.Stat, Sarit E Assouline, MD MSc, Joseph M Brandwein, MD, Steven M Chan, MD PhD, Signy Chow, MD FRCP(C), Dina Khalaf, BSc, MSc, MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MD, Dawn Maze, MDFRCPC,MSc, Mark D. Minden, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, David Sanford, MD, Aaron D Schimmer, MD PhD, Andre C. Schuh, Karen W.L. Yee, MD, Hassan Sibai, MBBS

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142990

Published: 2020

Journal Articles

Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-138943

Published: 2020

Journal Articles

Geographical Distance from Quaternary Treatment Center Does Not Impact Choice of Upfront Therapy, Clinical Trial Participation and Outcomes in Patients with Newly Diagnosed AML

Samantha A Hershenfeld, MD, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dawn Maze, MDFRCPC,MSc, Caroline J McNamara, MBBS, Mark D. Minden, Tracy Murphy, MDFRCP,FRCPath, Andre C. Schuh, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Aaron D Schimmer, MD PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-134645

Published: 2020

Journal Articles

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-141790

Published: 2020

Journal Articles

Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS

Tracy Murphy, MDFRCP,FRCPath, Brian Leber, MD, Mark R Bray, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dina Khalaf, BSc, MSc, MD, Dawn Maze, MDFRCPC,MSc, Caroline J McNamara, MBBS, Aaron D Schimmer, MD PhD, Andre C. Schuh, Hassan Sibai, MBBS, Graham Fletcher, Debbie Valiquette, Kylie Martin, BSc, RN, BSN, Mark D. Minden, Karen W.L. Yee, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-138822

Published: 2020

NARROW

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis

Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

Clinical Outcomes in De Novo Versus Secondary NPM1 -Mutated AML

Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Enasidenib in Combination with Venetoclax in IDH2 -Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial

Pregnancy Management and Outcomes in Patients with Myeloproliferative Neoplasms

Safety and Efficacy of JAK Inhibitor Therapy in BCR-ABL Negative MPN Patients with Underlying Portal Hypertension

Clinical Features and Long-Term Outcomes in a Molecularly-Annotated Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms

Clinical Significance of Emergent Leukocytosis in Patients with Myelofibrosis Receiving JAK Inhibitor Therapy

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA

Geographical Distance from Quaternary Treatment Center Does Not Impact Choice of Upfront Therapy, Clinical Trial Participation and Outcomes in Patients with Newly Diagnosed AML

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only